“After founding two pharmaceutical companies, I wanted to create something for myself that I could start taking right away to improve the course of my life.”
B.A. Cell Biology & Entrepreneurship, University of California, Berkeley
“Much of this is new research and constitutes a fundamental discovery on how we could change aging.”
Propion was founded to tackle one of the most overlooked drivers of aging: dysregulated tryptophan metabolism. Our mission is to create products that address aging at its root, guided by real science not trends.
Propion is built around the science of two gut metabolites, indole-3-propionic acid (Propion 1™) and indolepropionamide (Propion 2™). Our first product, Propion BLEND™, is the optimal blend of precursor ingredients your gut needs to create Propion 1™ and Propion 2™.
Rachel Karry is a mission-driven strategist who bridges culture, wellness, and sports to build purpose-driven brands and partnerships. As a Partner at WAU Ventures and Co-Founder & President of World Artists United, she brings deep expertise in brand storytelling, creative direction, and cross-sector growth to Propion.
Dr. Burkhard Poeggeler has been affiliated with the Georg-August-University Göttingen in Germany for more than 30 years and works on the biochemistry and pharmacology of prosurvival signaling. One focus of his research is using a holistic nutritive healthcare approach to aging. Over 100 Pubmed listed publications demonstrate his research on bioenergetic agents. Formerly the founder of a startup which tried to fund research on indole-3-propionic acid (Propion 1™) as a therapeutic for Alzheimer’s disease, Poeggeler helped to discover Propion 1™ and related compounds. He is the author of a textbook on the amino acid tryptophan and its metabolism. Editor of foremost textbook on tryptophan.
Scicinski is a drug discovery and development scientist, executive, and problem solver with a track record in new pharmaceutical product discovery and development. He has more than 35 years’ experience in the pharmaceutical and biotech industries, in both start-up and large corporate environments (GSK, Nuada, ALZA, EpicentRx), providing leadership for programs in drug discovery from hit identification to lead selection and for development projects including CMC, IND-enabling activities, clinical trial operations and regulatory filings and communication. Dr. Scicinski is a Fellow of the Royal Society of Chemistry with Chartered Chemist Status and holds a PhD from CambridgeUniversity and BSc hons from Imperial College, London. He has co-authored over 170 peer-reviewed publications, patents, abstracts and book chapters.
Zorgani is an internationally sought after scientist, speaker, and advisor with a background in product development and a specialized social media following for his expertise in microbiology. He advises Propion on product design, product validation, and social networking.
Andrews’ career can partially be measured in the millions of lives he has saved and improved by coinventing blockbuster drugs such as tissue plasminogen activator, beta-seron, and recombinant human growth hormone. He also led the team which discovered the human telomerase enzyme and has spoken at over 100 conferences about his research on telomeres.